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Several synthetic peptides, modelled from a Ca”-binding loop of the EF-hand family of proteins, were prepared containing cysteine residues. The 
peptide, GDKNADGFICFEEL, was labelled covalently at the cysteine residue (loop position 9) with iodoacetamidosalicylic a id. This novel 
conjugate is a metal-binding loop containing a salicylic acid side chain that could not only chelate Tb3’ in conjunction with the other chelating 
groups in the sequence, but could also sensitize Tb3+ luminescence. The loop had a high Tb’+ aftinity, with stoichiometric binding observed under 
experimental conditions. The luminescence from the Tb”-peptide complex was more than lo-fold greater than the luminescence reported from 
a related peptide which contained Trp as the Tb’+ donor at loop position 7. This peptide has significant potential for use in lanthanide-based 
time-resolved luminescence immunoassays. 
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1. INTRODUCTION 
There exists a family of Ca2’-binding proteins that 
bind the metal ion in a common motif of a-helix, loop, 
a-helix in the primary sequence. The metal-binding loop 
portion consists of 12 amino acids that chelate metal 
ions (Ca”, Mg2+, Tb3+ and Eu3+) through ligand groups 
at positions 1, 3, 5, 7, 9 and 12 of the loop [1,2]. The 
carbonyl oxygen of the peptide backbone at position 7 
is a ligand, while at positions 1,3, 5,9 and 12, chelation 
involves the residue side chains. 
Recently, a consensus sequence Ca*‘-binding loop 
was derived from a database of more than 200 species- 
variant loops [3] and modified to include different in- 
trinsic chromophores at different non-chelating loop 
positions [4]. That study showed that the sensitized lu- 
minescence of a bound Tb3+ ion is particularly high in 
the 14mer peptide, G(DKNADGWIEFEE)L. The 
donor chromophore, tryptophan, was at position 7 of 
the loop, where chelation to the Tb3+ is through the 
backbone carbonyl group. Replacement of the native 
CD loop of the Ca2’-binding protein, oncomodulin, 
with this consensus equence results in a very high level 
of luminescence from a bound Tb3+ ion [5], relative to 
Tb3+ luminescence from a single residue oncomodulin 
mutant, Y57W, in which the chromophore was placed 
at position 7 of the existing CD loop. From a series of 
oncomodulin mutants, the authors found that efficient 
Tb3+ sensitization requires that the donor+Tb3’ dis- 
tance to be ~10 A and therefore suggested that Dexter- 
type electron exchange is the mechanism of energy 
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transfer [6]. Another oncomodulin mutant was pre- 
pared with the consensus CD loop sequence, but con- 
taining a cysteine at loop position 7. This allowed the 
testing of the ability of various sulthydryl-reactive chro- 
mophores to sensitize lanthanide luminescence [7]. This 
mutant labelled with iodoacetamidosalicylic acid 
(IASA) was found to be one of the best donors for Tb”+ 
bound in the CD loop. Although salicylic acid conju- 
gated to diethylenetriaminepentaacetic acid (DTPA) is 
already known to directly chelate Tb3’ and sensitize 
Tb3+ luminescence [8], sensitization in the IASA-la- 
belled oncomodulin mutant does not involve direct che- 
lation by the salicylic acid moiety since the CD loop 
provides all the ligands for the metal ion. Therefore, if 
a salicylic acid conjugate could be one of the ligands, in 
conjugation with chelation by the remaining key resi- 
dues of the binding loop in the protein, an even greater 
level of Tb3+ sensitization could be anticipated due to 
the effective reduction in the salicylic acid-Tb3’ dis- 
tance. 
In this study, 14mer peptides were synthesized con- 
taining cysteine at chelating positions 5 and 9 and non- 
chelating position 7, to allow labelling with IASA and 
comparison of levels of sensitized luminescence from 
added Tb3+. 
2. MATERIALS AND METHODS 
Three 14mer peptides were synthesized by methods previously out- 
lined [4]: GDKNACFIEFEEL (Cys’), GDKNADGCIEFEEL (Cys’) 
and GDKNADGFICFEEL (Cys’); i.e. cysteine at position 5, 7 and 
9 of the binding loop, respectively (note: residues 1 and 14 of the 
peptide flank the 12-residue binding-loop sequence). Modification of 
the peptides with iodoacetamidosalicylic a id (IASA) and subsequent 
purification was as previously reported [7,9]. Solutions of IASA- Cys’, 
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IASA-Cys’ and IASA-Cys’ tappro~mat~ly 8.5 PM) were prepared in 
50 mM PIPES, pH 7.0, using &r,,r = 9,100 M-’ cm-’ for IASA. Lumi- 
nescence titrations were carried out by adding aliquots of a 1 mM 
stock of TbCI, solution to 2 ml of peptide. Tb” luminescence was 
measured on a SLM 8000C spectrofluorimeter, with data collection 
by a titration macro. Excitation was at 310 nm, emission was at 545 
nm, the temperature was 20°C and all slits were 4 am. 
3. RESULTS 
Fig. 1 shows the effect of varying the position of the 
IASA-labelled cysteine in the 14mer peptide on the 
amount of Tb3+ lumine~nce obtained. Clearly, the 
highest Tb3+ signal came from Tb’+ bound to IASA- 
Cys’. This suggested that, upon replacing the chelating 
glutamic acid at position 9 with an IASA-labelled cyste- 
ine residue, the resulting novel, chelating peptide side 
chain formed part of the coordination sphere of the 
bound Tb3+ ion. The amity of IASA-Cys9 for Tb3* was 
significant, with stoichiometric binding observed (Fig. 
1). 
IASA-Cys7 is the labelled consensus equence peptide 
that, in the CD loop of oncomodulin, gave a very high 
level of Tb3” luminescence [7]. Since chelation at posi- 
tion 7 of the loop is by the backbone carbonyl, the 
through-space energy transfer from salicylic acid to 
Tb3+ is significantly less than when the salicylic acid is 
able to chelate the lanthanide directly, as in IASA-Cys9. 
Placement of IASA-labelled cysteine at chelating posi- 
tion 5, in place of the chelating aspartic acid, did not 
produce the level of Tb3+ signal found with IASA-Cysg. 
This suggests that IASA-Cys’ was not able to improvise 
a conformation that allowed complete filling of the co- 
ordination sphere of Tb3+. 
4. DISCUSSION 
Recognition of the potential of lanthanide-based, 
time- resolved luminescence assays as an inexpensive, 
safe alternative to radioisotope-based assays has grown 
in recent years. In our laboratory, we have been focus- 
ing on the area of protein and peptide-based lanthanide 
chelation systems [4,5,7,9] which grew from the study of 
EF-hand Ca2’-binding proteins. In this study, the po- 
tential of hybridizing the chelating abilities of a Ca2’- 
binding peptide and salicylic acid was explored in order 
to maximize the energy transfer from salicylic acid to 
Tb3’. Introduction of salicylic acid as a chelating side 
chain in the peptide was done via labelling of a cysteine 
group at loop position 5 or 9 with iodoacetamidosali- 
cylic acid (IASA). Salicylic acid was also introduced as 
a non-chelating donor by labelling of a cysteine at loop 
position 7. Upon the addition of Tb3+, IASA-Cys’ 
clearly gave the largest signal, consistent with the model 
of Tb3+ chelation by both sahcylic acid and the peptide. 
There must be certain conformational constraints pres- 
ent because IASA-Cys’ did not produce the same level 
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Fig. 1. Tb” titration of IASA-14mers with cysteine at different posi- 
tions. Aliquots of a 1 mM Tb3’ stock solution were added to 2 ml of 
IASA-14mer (8.5 ,&I), with salicylic acid at position 5 (o), 7 (0) and 
9 (A) of the loop. Buffer was 50 mM PIPES, pH 7.0. Excitation = 310 
nm and emission = 545 nm. 
of Tb3+ luminescence as IASA-Cys9, although the same 
number of potential ligands are present in. both pep- 
tides. It is known that Ioop residues l-5 are more tightly 
packed than residues 7-12, and this may explain the 
apparently lower sensitivity of IASA-Cys’. The signal 
from IASA-Cys7 was also lower than that from IASA- 
Cys’ (approximately one-sixth), but this was expected 
since Tb3+ bound in IASA-Cys7 would have all of its 
coordination sphere filled by peptide side chains, ieav- 
ing salicyhc acid + Tb3+ energy transfer to occur 
through a greater distance in space. The improvement 
in signal from IASA-Cys’ over that from peptides previ- 
ously reported with the chromophore (Trp) at position 
7 [4] was greater than lo-fold which reflects not only the 
importance of the donor-acceptor distance, but the dif- 
ference between the chromophores’ sensitizing abihties. 
In conclusion, combining the chelation ability of a 
Ca2*-binding loop with the chelating and luminescent 
properties of salicylic acid produced a highly effective 
method of sensitizing Tb3+ l~inescence. It remains to 
be seen if inclusion of IASA-Cys’ as one of the loops in 
a Ca2’-binding protein, such as oncomodulin, would 
produce levels of Tb3+ luminescence higher than those 
currently observed [5,7]. 
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